Two similarly designed confirmation studies demonstrated opposing results with increased hematoma volume and a higher risk of recurrence in one study [9] versus no effect on recurrence in preoperative ACE inhibitor users in the other [10]. The gene discussed is ACE; the disease is hematoma.